The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

We recently published 10 Big Names Bleed Double Digits. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Hims & Hers Health stock missed on earnings last night. The company grew sales 73% and profits tripled, but Wall Street ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

(Reuters) -Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...